Nivolumab plus Ipilimumab plus platinum-doublet chemotherapy (Opdivo® plus Yervoy®). HTA ID: 21014

Assessment Status Rapid Review Complete
HTA ID 21014
Drug Nivolumab plus ipilimumab plus platinum-doublet chemotherapy
Brand Opdivo® plus Yervoy®
Indication For the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients whose tumours have no sensitising EGFR mutation or ALK translocation.
Assessment Process
Rapid review commissioned 31/03/2021
Rapid review completed 30/04/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that nivolumab in combination with ipilimumab plus platinum-doublet chemotherapy not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement following confidential price negotiations March 2022.